Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ROSUVASTATIN
IPS Healthcare Limited
10 Milligram
Film Coated Tablet
2010-10-08
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PPA1659/003/001 Case No: 2085239 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to IPS HEALTHCARE LIMITED STERLING HOUSE, 501 MIDDLETON ROAD, CHADDERTON, OLDHAM, LANCASHIRE OL9 9LY, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product CRESTOR 10MG FILM-COATED TABLETS the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 08/10/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 11/10/2010_ _CRN 2085239_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Crestor 10mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg rosuvastatin (as rosuvastatin calcium). Each tablets contains 91.3 mg lactose monohydrate. For a full list of excipients, _see Section 6.1._ 3 PHARMACEUTICAL FORM Film-coated tablet. _Product imported from United Kingdom:_ Round, pink coloured tablets, intag1iated with _'ZD4S22' _and '10' on one side and plain on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TREATMENT OF HYPERCHOLESTEROLAEMIA Adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia (type IIa i Read the complete document